Hafif klinik seyirli mediyastinal lenf nodu mukormikozisi

Öz

Mukormikozis; özellikle diyabetes mellitus ve hematolojik malignitesi olan hastalarda ortaya çıkan, nadir fakat sıklıkla ölümcül seyreden, fırsatçı bir mantar enfeksiyonudur. Enfeksiyona genellikle sporların inhalasyonu neden olduğundan en sık paranazal sinüsler ve akciğerler etkilenir. Risk faktörleri arasında kontrolsüz diyabetes mellitus, hematolojik maligniteler ve uzun süreli kortikosteroid kullanımı yer alır. Sıklıkla bakteriyel pnömoni gibi başlamaktadır, klinik ve radyolojik bulguları nonspesifiktir. Altta yatan nedenler tedavi edilmeli, cerrahi debridman yapılmalı ve uygun antifungal ilaçlar verilmelidir. Bu makalede pulmoner veya endobronşial tutulum olmaksızın, hafif klinik seyirli, çok nadir saptanan mediastinal lenf nodu mukormikozis olgusu literatür eşliğinde sunuldu.

Anahtar Kelimeler

• Mukormikozis
• mediyastinal lenf nodu
• diyabetes mellitus

Mediastinal lymph node mucormycosis with mild clinical course

Abstract

Mucormycosis is a rare but usually fatal opportunistic infection and expecially seen in patients with diabetes mellitus and hematologic malignancies. Since the infection is usually caused by inhalation of spores, the paranasal sinuses and lungs are most commonly affected. Risk factors include uncontrolled diabetes mellitus, hematological malignancies, and long-term corticosteroid use. Early diagnosis and treatment is important. Infection usually initiates like bacterial pnuemonia and clinic, radiologic findings are nonspesific. The underlying causes should be treated, surgical debridement should be performed, and appropriate antifungal drugs should be given. In this article, a very rare case of mediastinal lymph node mucormycosis with mild clinical course without pulmonary or endobronchial involvement is presented in the light of the literature.

Keywords

• Mucormycosis
• mediastinal lymp node
• diabetes mellitus

Kaynakça

1. 1. Tedder M, Spratt JA, Anstadt MP, Hegde SS, Tedder SD, Lowe JE. Pulmonary mucormycosis: results of medical and surgical therapy. Ann Thorac Surg 1994; 57: 1044-50.
2. 2. Lee FY, Mossad SB, Adal KA. Pulmonary mucormycosis: the last 30 years. Arch Intern Med 1999; 159: 1301-9.
3. 3. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41: 634-53.
4. 4. Donohue JF, Scott RJ, Walker DH, Bromberg PA. Phycomycetes: a cause of bronchial obstruction. South Med J 1980; 73: 734-6.
5. 5. Taşbakan MS, Çeviker Y, Sipahi OR, Metin D,Veral A, Susur A, Sayıner A, Bacakoğlu F. Pansitopenik bir olguda rinoserebral ve akciğer mukormikozu ve aspregillozu. Ankem Dergisi 2010;24(1):42-45.
6. 6. Hamilos G, Samonis G, Kontoyiannis DP. Pulmonary mucormycosis, Semin. Respir. Crit. Care Med. 32 (2011) 693–702.
7. 7. Choi H, Lee H, Jeon K, Suh GY, Shin S, Kim HK, Kim H, Factors affecting surgical resection and treatment outcomes in patients with pulmonary mucormycosis, J. Thorac. Dis. 11 (3) (2019) 892–900